



# ACUTE KIDNEY INJURY (AKI) IN BURN PATIENTS

Dr. dr. Mohammad Rudiansyah, MKes, SpPD, K-GH, FINASIM

Division of Nephrology & Hypertension, Department of Internal Medicine Faculty of Medicine  
Universitas Lambung Mangkurat/Ulin Hospital Banjarmasin, Indonesia

# CURRICULUM VITAE

**Dr. dr. H. Mohammad Rudiansyah, MKes, SpPD-KGH, FINASIM**

Tgl lahir : Banjarmasin, 3 Mei 1970

Alamat : Jl. Dharma Praja VII/29. Banjarmasin

## Pendidikan :

- Dokter ,FK. UGM 1996
- S-2 Ilmu Penyakit Tropis, FK. UGM 2000
- Spesialis Penyakit Dalam, FK UGM 2008
- Kursus Hemodialisa, RSU Dr Syaiful Anwar, Malang 2010
- Training Health Services in Renal Center, Kitchen, Quality Assurance, Khoo Teck Phuat Hospital, Singapore 2010
- Konsultan Ginjal & Hipertensi, RSUP Dr Hasan Sadikin, Bandung 2017
- S-3 Ilmu Kedokteran, FK UNPAD 2016-2020

## Pekerjaan :

- Kepala Bagian Ilmu Kesehatan Masyarakat, FK Unlam 2001-2003
- Ketua Penelitian & Pengembangan, FK Unlam 2001-2003
- Kepala Unit Transfusi Darah – PMI Cab. Banjarmasin 2003-2008
- Koordinator Dokter Medical Cek Up, RSUD Ulin Banjarmasin 2010-2012
- Ketua Komite Keselamatan Pasien, RSUD Ulin Banjarmasin 2010-2012
- Penanggung jawab R. Hemodialisis, RSUD Ulin Banjarmasin 2010- Sekarang
- Ketua Tim Kendali Mutu & Kendali Biaya BPJS Kes Prov Kalsel 2019-2023
- Anggota Dewan Pengawas RSUD Sultan Suriansyah Banjarmasin 2022-sekarang

## Organisasi :

- IDI, PAPDI, PERNEFRI, IAKMI, PDKMI
- Ketua PERALMUNI Cabang Kalimantan Selatan, 2023-sekarang
- Ketua IDI Wilayah Kalimantan Selatan, 2012-2022
- Ketua Komite Internship Dokter Indonesia Prov. Kalsel 2012-2023
- Wakil Ketua PAPDI Cabang Kalsel 2018-sekarang
- Direktur Klinik Dhuafa Tersenyum, 2013-sekarang
- Ketua Perhimpunan Klinik & Fasilitas Pelayanan Kesehatan Primer Indonesia (PKFI) Wil. Kalsel 2015-sekarang
- Penasehat INKAI Kota Banjarmasin 2016-2019
- Anggota PERNEFRI Korwil Jatim & Kalimantan 2017-sekarang
- Member of Accreditation & Certification Committee in American Society of Diagnostic & Interventional of Nephrology (ASDIN) 2018-2020





# OVERVIEW


- Acute kidney injury (AKI): **common and morbid** complication after severe burn → incidence 30%, mortality 80%.
- Burn-related kidney injury is classified as early (0–3 days after injury) or late (4–14 days after injury).
- Kidney Disease: Improving Global Outcomes (KDIGO) consensus defined stage and severity of AKI based on changes of serum creatinine and urine output across time.
- The reversal of the underlying cause is the first intervention.
- Unfortunately, no beneficial pharmacologic agents have been identified.

# DEFINITION

- AKI = an abrupt decrease in kidney function
- Both RIFLE and AKIN have been validated in burn ICUs → increased severity of AKI correlate closely with mortality and adverse renal outcomes

**Table 1 – RIFLE, AKIN, and KDIGO criteria for AKI [6].**

	RIFLE criteria	AKIN criteria	KDIGO criteria	Urine output
AKI definition	Increase in sCr of >50% baseline developing over <7 days	Increase in sCr of 0.3mg/dL or >50% developing over <48h	Increase in sCr of 0.3mg/dL developing over 48h or >50% developing over 7 days	UOP <0.5mg/kg/h for ≥6h
Staging				
Risk	1.5-1.9 times baseline sCr or GFR decrease >25%	1 1.5-1.9 times initial/baseline sCr or ≥0.3mg/dL increase in sCr	1.5-1.9 times initial/baseline sCr or ≥0.3mg/dL increase in sCr	<0.5mL/kg/h for 6-12h
Injury	2.0-2.9 times baseline sCr or GFR decrease >50%	2 2.0-2.9 times initial/baseline sCr	2.0-2.9 times initial/baseline sCr	<0.5mL/kg/h for ≥12h
Failure	3.0 times baseline sCr or increase in sCr to ≥4.0mg/dL with an acute increase of >0.5mg/dL or GFR decrease >75%	3 3.0 times initial/baseline sCr or increase in sCr to ≥4.0mg/dL with an acute increase of >0.5mg/dL or initiation of RRT	3.0 times initial/baseline sCr or increase in sCr to ≥4.0mg/dL or initiation of RRT	<0.3mL/kg/h for ≥24h or anuria for ≥12h
Loss	Need for RRT >4 weeks			
End stage	Need for RRT for >3months			



**Figure 3 | Conceptual model for AKI.** Red circles represent stages of AKI. Yellow circles represent potential antecedents of AKI, and the pink circle represents an intermediate stage (not yet defined). Thick arrows between circles represent risk factors associated with the initiation and progression of disease that can be affected or detected by interventions. Purple circles represent outcomes of AKI. “Complications” refers to all complications of AKI, including efforts at prevention and treatment, and complications in other organ systems. AKI, acute kidney injury; GFR, glomerular filtration rate. Adapted from Murray PT, Devarajan P, Levey AS, *et al.* A framework and key research questions in AKI diagnosis and staging in different environments. *Clin J Am Soc Nephrol* 2008; 3: 864–868 with permission from American Society of Nephrology<sup>45</sup> conveyed through Copyright Clearance Center, Inc.; accessed <http://cjasn.asnjournals.org/content/3/3/864.full>


# ETIOLOGY

**Table 6 | Causes of AKI: exposures and susceptibilities for non-specific AKI**


Exposures	Susceptibilities
Sepsis	Dehydration or volume depletion
Critical illness	Advanced age
Circulatory shock	Female gender
Burns	Black race
Trauma	CKD
Cardiac surgery (especially with CPB)	Chronic diseases (heart, lung, liver)
Major noncardiac surgery	Diabetes mellitus
Nephrotoxic drugs	Cancer
Radiocontrast agents	Anemia
Poisonous plants and animals	

CKD, chronic kidney disease; CPB, cardiopulmonary bypass.


# Pathophysiology of prerenal AKI (BURN)












**Fig. 1 – Common causes of early and late AKI after severe burn.**

AKI is not dependent only on the quantity of fluid given, but also on the degree of shock after severe burn.

# Early AKI

- Substantial fluid loss from burn wound + fluid shift from the intravascular to interstitial space → hypovolemia, ↓cardiac output → ↓renal blood flow → ischemia, cellular injury and death.
- Ischemic injury yields oxygen free radicals → tubular damage, disturbance of tight junctions → obstructing cellular casts → urine backflow → ↓GFR
- ↑sympathetic activity + insufficient adrenal response, hypovolemia-induced myocardial ischemia, and direct myocardial suppression by TNF-alpha or some other factor released from myocytes → cardiac dysfunction
- Rhabdomyolysis → muscle fluid sequestration, intrarenal vasoconstriction, release of toxic intracellular components into the systemic circulation → oxidative injury and inflammation → ischemic tubular injury, AKI
- Released myoglobin precipitates in renal tubules → afferent renal arteriolar vasoconstriction + O<sub>2</sub> free radicals



**Fig. 1 – Common causes of early and late AKI after severe burn.**




# Late AKI

- Nephrotoxic agents (aminoglycosides, some cephalosporins, iv contrast agents) are often given to burn patients.
- Sepsis and septic shock are the leading cause of death in the ICU (up to 87% of AKI cases in the burn ICU). Multifactorial mechanism of sepsis-related AKI:

↓vascular resistance (a high-flow, low pressure state) → systemic arterial vasodilation.

Bacteria activate sepsis-associated cytokines → endothelial damage, vasoparalysis, and a procoagulant state → profound hypotension → activates sympathetic nervous system and the renin-angiotensin-aldosterone response → ↑cardiac output state.




# RISK FACTORS

- AKI and RRT is common in ICU patients with burn injuries.
- Patients with old age, chronic hypertension, diabetes mellitus, high TBSA%, high ABSI score, inhalation injury, rhabdomyolysis, surgery, high APACHE II score, high SOFA score, sepsis, and need for mechanical ventilation are at risk for post-burn AKI.

**Fig. 3** Risk factors for acute kidney injury in burn patients admitted to the intensive care unit. The contribution from the various risk factors were statistically weighted and adjusted to a single scale. Odds ratios (OR) for continuous risk factors were derived from standardised mean differences. CI, confidence interval; ABSI, Abbreviated Burn Severity Index; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Function Assessment; TBSA, Total Body Surface Area; BMI, body mass index; MAP, mean arterial pressure


# DIAGNOSIS

- The diagnosis of AKI after burn can be challenging, as UOP and sCr can be relatively normal even with significant renal injury.
- ↓UOP is often the first physiologic sign of renal injury in burn (very specific, although it is not sensitive)
- Microscopic and biochemical urine sediment analyses :
  - Prerenal condition : normal urinary sediment or hyaline casts, concentrated urine, in oliguric patient.
  - acute tubular necrosis : tubular epithelial cells, granular casts, and epithelial cell casts
  - Rhabdomyolysis → myoglobinuria → pigmented casts on microscopic evaluation and the classic dissociation between positive blood in dipstick urinalysis with absent red blood cells on microscopy





- Particular serum and urinary biomarkers have shown utility in AKI prediction in critically ill patients, including burn injuries.



- Serum and urine NGAL, urinary TIMP-2, and IGFBP7 have superior results.
- Further studies are required to validate & establish cut-off values for cystatin C and urinary KIM-1




# **Biomarkers for Early Prediction of Acute Kidney Injury**

# Acute Kidney Injury Biomarkers

Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of Acute Kidney Injury. *Annu Rev Pharmacol Toxicol* 2008;48:463-493

## Biomarkers



## Biomarkers

Sensitive (early appearance)  
 Easy to detect  
 Specific (typical of organ injury)  
 Correlate with severity (prognosis)  
 Quantitatively describing the level of injury even in the absence of typical clinical signs  
 Capable to indicate treatment initiation (theragnostics)

### Potential urinary biomarkers for early diagnosis of AKI

- |              |          |
|--------------|----------|
| NAG          | NGAL     |
| $\beta_2$ M  | CYR-61   |
| $\alpha_1$ M | IL-18    |
| RBP          | OPN      |
| Cystatin C   | FABP     |
| KIM-1        | NHE3     |
| Clusterin    | Fetuin A |
| Microalbumin |          |




### Delayed biomarkers for kidney injury

- ↑ Serum creatinine
- ↑ Blood urea nitrogen


## Late detections




# Potential Roles of Biomarkers in AKI



# Scenario to decrease mortality with early diagnosis



# Potential Biomarkers in AKI (Human Data)



# Promising Biomarkers for AKI

Marker	Sample	Timing	Commercial test?
<b>NGAL</b>	<b>Plasma</b>	<b>Early</b>	<b>Biosite</b>
Cystatin C	Plasma	Intermediate	Dade- Behring
<b>NGAL</b>	<b>Urine</b>	<b>Early</b>	<b>Abott</b>
IL-18	Urine	Intermediate	None
KIM-1	Urine	Intermediate	None



# TREATMENT

- The most important: identification, reversal of underlying cause, correction of electrolyte and fluid derangements.
- If the injury continues to progress despite conventional therapy → RRT should be judiciously initiated to prevent complications.



	AKI Stage			
	High Risk	1	2	3
Discontinue all nephrotoxic agents when possible	Solid	Solid	Solid	Solid
Ensure volume status and perfusion pressure	Solid	Solid	Solid	Solid
Consider functional hemodynamic monitoring	Solid	Solid	Solid	Solid
Monitor Serum creatinine and urine output	Solid	Solid	Solid	Solid
Avoid hyperglycemia	Solid	Solid	Solid	Solid
Consider alternatives to radiocontrast procedures	Solid	Solid	Solid	Solid
Non-invasive diagnostic workup		Graded	Graded	Graded
Consider invasive diagnostic workup			Graded	Graded
Check for changes in drug dosing			Graded	Graded
Consider Renal Replacement Therapy			Graded	Graded
Consider ICU admission			Graded	Graded
Avoid subclavian catheters if possible				Graded

**Figure 4 | Stage-based management of AKI.** Shading of boxes indicates priority of action—solid shading indicates actions that are equally appropriate at all stages whereas graded shading indicates increasing priority as intensity increases. AKI, acute kidney injury; ICU, intensive-care unit.

# TREATMENT

- Early AKI (poor renal perfusion) → early & aggressive crystalloid resuscitation utilizing Parkland formula. Adjust rates & solutions based on the individual's physiologic status to optimize renal perfusion without over-resuscitation.
- Colloids (albumin/ fresh frozen plasma) improve intravascular osmotic pressure, expand intravascular volume, and limit edema in unburned tissue → can be used either early in resuscitation or later if crystalloid being used is excessive
- if initial maneuvers do not maintain a mean arterial pressure over 60mm Hg → norepinephrine to support blood pressure and renal perfusion.
- Vitamin C is a possible adjunct because of its antioxidant effects.

# TREATMENT

- Late AKI is often multifactorial and associated with sepsis and multi-organ failure.
- Early recognition of sepsis : increasing insulin resistance, feeding intolerance, or elevation of acute phase reactants → Intervention: goal-directed therapy
- When infectious organism is identified → antibiotics, dose accordingly to renal function status → goal : treat a local infection and gain source control before it spreads systemically and causes septic shock and end-organ damage.
- Nephrotoxic drugs (e.g., aminoglycosides, IV contrast, NSAIDs) should be avoided / discontinued.

# TREATMENT -- RRT

- About 12% of AKI patients in burn ICU received RRT
- RRT is not of benefit in most cases of AKI in burn patients, but if renal function continues to worsen despite initial interventions, RRT should be utilized early to prevent complications (severe metabolic derangements or fluid overload).

**Table 3 – Modalities of renal replacement therapy.**

	IHD	SLED	CRRT
Name	Intermittent hemodialysis	Sustained low efficiency dialysis	Continuous renal replacement therapy
Blood flow	300-400mL/min	200-300mL/min	50-200mL/min
Dialysate flow	500-800mL/min	1-2L/h	2-3L/h
Hemodynamic stability	Poor (hypotension common)	Good	Good
Duration	3-4h, 3x/week	6-12h daily	Continuous
Access	Fistula or vascath	Fistula or vascath	Vascath only
Anticoagulation use	None	Rare	Always

Abbreviations: CRRT (continuous renal replacement therapy), IHD (intermittent hemodialysis), SLED (sustained low-efficiency dialysis).



# AKI RECOVERY AND COMPLICATIONS

- Patients with severe burn who develop AKI ↑↑ mortality.
- Diagnosis is challenging → measure UOP & SCr
- Factors increasing mortality: severity of AKI , older age, larger % total body surface area, and higher incidence of inhalational injury.
- AKI may lead to more than just adverse renal outcome → risk of stroke, coronary events, and all-cause mortality → observation 1-3 months after discharge is necessary in severe AKI cases, to prevent recurrent AKI or transition to CKD.

A retrospective study in burn patients admitted to Dr. Soetomo Hospital Burn Center (2018-2020):

Complications of burn patients with AKI:

Risk factors for mortality in burn patients with AKI:

Complications	n (%)
Sepsis	9 (50)
Inhalation Injury	11 (61)
Hypoalbuminemia	16 (89)
Anemia	7 (39)
Thrombocytopenia	2 (11)
Metabolic acidosis	3 (17)
Hyperkalemia	2 (11)
Pneumonia	3 (17)

Variables	OR	P value	CI 95%
Inhalation trauma	1.60	0.034	0.935-2.737
Sepsis	1.50	0.058	0.945-2.381
Hypoalbuminemia	5.50	0.180	0.385-78.573
TBSA	28.0	0.011	1,208-648,809
Age	0.57	0.017	0.301-1.08

# TAKE HOME MESSAGES

- AKI is a common and morbid complication of severe burn.
- The most important aspects of therapy are timely identification, the reversal of the underlying cause, the mitigation of nephrotoxicity, and the correction of electrolyte and fluid derangements.
- An episode of AKI may have lasting effects and increase the risk for CKD, ESRD, cardiac events, stroke, and long-term mortality → further research is needed regarding possible long-term consequences.



**THANK YOU**